Angion Biomedica

Elicio uses struggling Angion as route to Nasdaq ahead of cancer vaccine's phase 2 move
Fierce Biotech
Tue, 01/17/23 - 10:18 am
Elicio Therapeutics
NASDAQ
cancer vaccines
clinical trials
Angion Biomedica
Following a host of trial flops, Angion halts R&D work, searches for ‘strategic alternatives’
Endpoints
Tue, 07/26/22 - 11:07 am
Angion Biomedica
R&D
Angion’s kidney transplant dream dies
EP Vantage
Wed, 10/27/21 - 10:52 am
Angion Biomedica
ANG-3777
kidney injury
Vifor Pharma